Live Nation Entertainment, Inc. vs TransMedics Group Inc — how do they compare? Live Nation Entertainment, Inc. trades at $180.98 (market cap $42.09B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: Live Nation Entertainment, Inc. is far larger — about 16.6× TransMedics Group Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| LYV | TMDX | |
|---|---|---|
Market Cap | $42.09B | $2.54B |
Sector | Industrials | Technology |
52-Week High | $186.59 | $150.42 |
52-Week Low | $125.61 | $61.99 |
Enterprise Value | $43.59B | $2.94B |
Trailing returns across standard periods
Latest headlines on both assets
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →